Fig. 3From: Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group studyProgression-free survival of all patients stratified by a clinical risk and b molecular subgroupBack to article page